A brief screening tool for depression in psoriasis patients: The Two Questions Test in clinical practice. Issue 3 (21st November 2021)

• Record Type: Journal Article
• Authors: Hölsken, Stefanie; Krefting, Frederik; Schneider, Lea; Benson, Sven; Schedlowski, Manfred; Sondermann, Wiebke
• Is Part Of: Journal of dermatology. Volume 49:Issue 3(2022)
• Page Start: 341
• Page End: 348
• Publication Date: 2021-11-21
• Subjects: depression -- mental well‐being -- psoriasis -- screening -- Two Questions Test; Dermatology -- Periodicals; Dermatology -- Japan -- Periodicals; Skin -- Diseases -- Periodicals; 616.5005
• DOI: 10.1111/1346-8138.16241
• Languages: English
• ISSNs: 0385-2407

Abstract

Abstract: Patients suffering from chronic inflammatory diseases such as psoriasis are prone to develop depressive symptoms. However, within the time constraints of dermatological clinics, depressive symptoms in psoriasis patients are often overlooked and thus underdiagnosed. The Two Questions Test may serve as a quick screening tool for an initial assessment of depressive burden in these patients. We evaluated its usefulness in the clinical context analyzing the records of patients starting systemic treatment for psoriasis with a selective interleukin (IL)23‐ or IL17A‐inhibitor. In a total sample of N = 139 patients, baseline Two Questions Test scores were analyzed together with measures of psoriatic and psychiatric symptoms. In addition, the development of the Two Questions Test scores over the course of the first 28 weeks of treatment was assessed. No association was found between the Two Questions Test scores and skin symptoms measured by the Psoriasis Area and Severity Index and the visibility of skin lesions. However, skin related quality of life analyzed with the Dermatology Life Quality Index was associated with the Two Questions Test scores. In addition, the longitudinal analysis revealed improvement in Two Questions Test outcomes over the course of patients' treatment. These results indicate the Two Questions Test's usefulness both as an initial screening tool of depressive symptoms, as well as in its use as a sensitive tool for the repeated assessment of depressive symptoms in psoriasis patients.